Japan's Major Generics Drug Maker Sawai Pharmaceutical Looks To M&A For Growth
This article was originally published in PharmAsia News
Executive Summary
In an interview with Reuters, Japan's major generic drug maker Sawai Pharmaceutical President Mitsuo Sawai disclosed a goal of doubling sales in five years to become a ¥100 billion company by 2014. Sawai explained that the scale will allow the company to fully utilize its specialty in generics business. To achieve the goal, enriching product lineup and expanding business scale through mergers and acquisitions are necessary, Sawai stated. He further set eye care and tropical products as candidates for partnership. Regarding Daiichi Sankyo's entry to the generics market through buying Indian firm Ranbaxy, Sawai estimated that the joint Daiichi Sankyo-Ranbaxy will first focus on expanding markets in developing countries. He also doubted that Daiichi Sankyo would focus on generics business. As a new drug discovery company, promoting generic versions of its own brand products is equal to wrapping a rope around the neck, Sawai added. (Click here for more - Japanese language) "Sawai Pharmaceutical President-M&A Necessary To Grow Sales To 100 Billion" - Reuters Japan (8/28/08)
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.